



2018 APASL Single Topic Conference on Hepatitis B Virus Taipei

HBV

APASL STC 2018

Towards Hepatitis B Elimination - Following Hepatitis C Cure

June 22-24

Taipei International Convention Center
Taipei, Taiwan



Antonio Bertoletti

CURRENT POSITIONS

Professor,
Duke-NUS Medical School
Division Emerging Infectious Diseases,
Singapore

Antonio Bertoletti, MD is an expert in the field of viral hepatitis, with a specific interest in the immunopathogenesis of HBV infection.. He began working in viral hepatitis as a medical student at the University of Parma (Italy). During his MD specialization (1991) in Infectious Diseases he spent two years at The Scripps Research Institute (La Jolla) characterizing for the first time the *Hepatitis B virus* (HBV) specific cytotoxic T cell response in man. He returned to the University of Parma, where he worked in the Department of Infectious Diseases as a Clinical Scientist continuing his study of human HBV specific T cells. Dr. Bertoletti then joined (1995) the MRC Unit in the Gambia, as Senior Immunologist, to study HIV-2 specific T cell Immunity before accepting a position of Senior Lecturer at “The UCL Institute of Hepatology” at University College of London (UK) (1997).

In 2006 he moved to Singapore where he was the Director of Infection and Immunity Program at the Singapore Institute for Clinical Sciences (A*STAR) until 2013 before moving in 2013 at the Emerging Viral Disease Program at Duke-NUS Medical School.

He maintains an Adjunct Position as Research Director, Viral Hepatitis at the Singapore Institutes for Clinical Sciences and is Honorary Professor of School of Immunity and Infection, College of Medical and Dental Science, University of Birmingham, Edgbaston, UK. He collaborates and/or sits in advisory boards meeting of different companies (Roche, GSK, J&J, Gilead) and is the current Vice-President of the Singapore Society of Immunology. His current research is focus on the development of new immunological based therapies (TCR-redirected T cells, HLA-peptide specific antibodies) for the treatment of HBV and Hepatocellularcarcinoma and on the characterization of human intrasinusoidal hepatic immune system.